Table 4 Oral metabolites with antifungal properties that were deferentially expressed among study groups.
Metabolites | OT vs C | AT vs C | OT vs AT |
|---|---|---|---|
Expression (fold change, p-value) | Expression (fold change, p-value) | Expression (fold change, p-value) | |
Fatty acyls (FA) | |||
Linoleamide | Down (-3.42, 1.22E-04) | Down (-11.44, 1.22E-04) | Up (3.35, 1.22E-04) |
Oleamide | Down (-3396.9, 3.12E-22) | Down (-305.2, 3.12E-22) | Down (-11.13, 3.12E-22) |
Palmitic amide | Down (-3.81, 1.51E-03) | Down (-7.57, 1.51E-03) | Up (1.99, 1.51E-03) |
Stearamide | Down (-1.63, 5.15E-04) | Down (-9.01, 5.15E-04) | Up (5.54, 5.15E-04) |
undecan-2-one | Up (2719.6, 1.35E-15) | Up (488.3, 1.35E-15) | Up (5.57, 1.35E-15) |
Glycerolipid (GL) | |||
1-monopalmitin | Up (7.36, 1.22E-05) | Up (4.482, 1.22E-05) | Up (2.881, 1.22E-05) |
Carboxylic acids (CA) and derivatives | |||
Dichloroacetate (DCA) | Up (27.62, 3.35E-04) | Up (7.79, 3.35E-04) | Up (3.55, 3.35E-04) |
Organonitrogen compounds | |||
Cyclohexylammonium | Down (-1813.2, 4.34E-14) | Down (-213.9, 4.34E-14) | Down (-8.48, 4.34E-14) |
Furans | |||
Isolimonic acid | Down (-2.74, 2.08E-24) | Up (410.0, 2.08E-24) | Down (-1123.6, 2.08E-24) |
